
    
      The purpose of this study is to determine the efficacy of the use of intravenous low-dose
      ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the
      changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy
      and inflammatory serum markers (IL-6, TNF-alpha).
    
  